Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
Elizabeth R. Plimack
Research Funding - Merck
Yu-Ning Wong
No relevant relationships to disclose
Lois Malizzia
No relevant relationships to disclose
Alycia Corrigan
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Crystal Shereen Denlinger
No relevant relationships to disclose
Susan Roethke
No relevant relationships to disclose
Colleen H. Tetzlaff
No relevant relationships to disclose
Gary R. Hudes
No relevant relationships to disclose